Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(50.0%)
N/A
2(50.0%)
4Total
Phase 3(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07222540Unknown

Expanded Access Program Evaluating SkinTE in the Treatment of Wagner 1 Diabetic Foot Ulcers

Role: lead

NCT06140303Phase 3Active Not Recruiting

SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

Role: lead

NCT05372809Phase 3Terminated

Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs

Role: lead

NCT03881267Not ApplicableCompleted

SkinTE® in the Treatment of Venous Leg Wounds

Role: lead

NCT03881254Not ApplicableCompleted

SkinTE™ in the Treatment of Diabetic Foot Wounds

Role: lead

All 5 trials loaded